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ABSTRACT
Background: Calcium electroporation (CaEP) is a novel therapeutic treatment that has been studied for cancer due to its 
selective killing cancer cells by necrosis and danger signals. Besides that, electrochemotherapy (ECT) is an effective lo-
cal treatment that involves the administration of chemotherapeutic drugs followed by delivery of electrical pulses to the 
tumor. The combination with ECT and CaEP has been reported in literature suggesting that additional response of immune 
system could have been enhanced by electroporation with calcium. This case, report on the successful treatment with CaEP 
combined with ECT for treatment of a regional metastasis in a feline model of malignant melanoma.
Case: A 9-year-old, mixed breed cat was referred to the veterinary clinic with a 2-month history of cutaneous peripalpebral 
plaque lesion (0.19 cm³) and a submandibular lymph node enlargement (0.5 cm³). Incisional biopsy of the cutaneous lesion 
and fine-needle aspiration of submandibular lymph node confirmed a cutaneous melanoma with submandibular lymph node 
metastasis. Tumor staging was set in T1N1M0 according to WHO staging criteria. ECT for the primary lesion and lymph 
node metastasis was proposed. For the ECT, bleomycin (15,000 UI/m²) application was performed intravenous followed 
by electroporation (8 pulses of 100 μs at 1000 V/cm, and 1 Hz) using a needle array electrode consisted of two parallel 
rows with six needles in each row. At 28-day post-ECT complete remission of the primary tumor and metastatic foci was 
achieved. However, 120 days after ECT, recurrence was observed in submandibular and retropharyngeal lymph nodes. A 
second ECT approach was performed adding to bleomycin the intra lymph nodal application of calcium gluconate. The 
dose of calcium gluconate was diluted in an isotonic 0.9% NaCl solution resulting in a low concentration at 9 mM, injected 
in both metastatic lymph nodes (submandibular total volume: 1.4 ml; retropharyngeal total volume: 0.5 mL) and pulses 
were delivered immediately after drug administration. No systemic adverse effects were observed. Local adverse effects 
were considered mild as transitory edema and ulceration post procedure. One-week post-ECT+CaEP, complete remission 
of local metastasis occurred. However, the patient achieved five months disease free interval, and died during a surgical 
approach, achieving nine months of survival time. 
Discussion: Feline cutaneous malignant melanoma is an aggressive disease with a short survival time for the patients 
with mean of 4.5 months. CaEP is a novel anticancer treatment that has been study in the past years due to its selective 
killing cancer cells by necrosis and danger signals. The CaEP induces supraphysiological calcium influx into neoplastic 
cells leading to acute ATP depletion and necrosis of tumor cells. This use could be an interesting therapeutic choice for 
both human and veterinary medicine. In this patient, it was demonstrated a good clinical response with its use, showing 
temporarily tumor remission from the case presented with disease free interval of five months when compared to other 
report of two months. This description showed that ECT associated with CaEP improved outcome of regional melanoma 
lymph node metastasis in a cat. However, further investigations are needed to understand the use of CaEP in patients with 
metastasis as well as evaluate the use of both modalities to determine its synergistic effect.
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INTRODUCTION
Calcium electroporation (CaEP) is a novel 
therapeutic perspective for patients with cutaneous 
metastasis of malignant melanoma [3] and remission 
of metastatic melanoma foci [4]. Its approach leads to 
supraphysiological calcium influx into neoplastic cells 
leading to acute ATP depletion killing cancer cells 
by necrosis and cellular danger signals (expression 
of ATP, calrecticulin and HMGB1) [7]. Besides this, 
electrochemotherapy is an effective local treatment 
that involves the administration of chemotherapeutic 
drugs followed by delivery of electrical pulses (elec-
troporation) to the tumor. 
This technique is mainly used on skin tumors, 
cutaneous metastasis of several tumors and head and 
neck cancers [9,13]. New evidences suggested on small 
skin metastasis that CaEP has a similar objective respon-
se rate compared to ECT with limited side effects [3]. 
The combination with ECT and CaEP has been reported 
in a dog with oral melanoma with resolution of regio-
nal metastasis 30 days after treatment, suggesting that 
additional response of immune system could have been 
enhanced by electroporation with calcium [8]. Taking 
into theses previous considerations, this report a des-
cription of ECT combined with CaEP for treatment of 
a regional metastasis in a cat with malignant melanoma.
CASE
The animal included were client-owned and 
written owner consent was obtained. A 9-years-old, 
mixed breed cat was referred to the veterinary clinic 
with a 2-month history of cutaneous peripalpebral 
plaque lesion (0.19 cm³) and a submandibular lymph 
node enlargement (0.5 cm³). Tumor volume was calcu-
lated as ab²π/6 (‘a’ is the larger diameter of the tumor 
nodule, and ‘b’ is the diameter of the tumor nodule 
perpendicular to ‘a’) [14]. Incisional biopsy of the cu-
taneous lesion and fine-needle aspiration (FNA) of sub-
mandibular lymph node were performed and confirmed 
a cutaneous melanoma with submandibular lymph node 
metastasis. Abdominal ultrasound, three-view thoracic 
radiograph, complete blood count and chemistry panel 
were performed and revealed no abnormalities. Tumor 
staging was set in T1N1M0 according to WHO staging 
criteria. Since the owner declined the surgical excision 
associated with systemic chemotherapy, ECT for the 
primary lesion (Figure 1A) and lymph node metas-
tasis (Figure 1C) was proposed. Electric pulses were 
administered in time intervals of 8-28 min after 5 min 
of intravenously injecting bleomycin sulfate1 [Cina-
leo®) at 15,000 IU/m² in bolus 1.05 mL] under general 
anesthesia. The cat was premedicated with pethidine2 
[Pethidine® - 0.3 mg/kg] injected intramuscularly; 
anesthetic induction was performed with propofol2 
[Provive® - 3 mg/kg] and ketamine3 [Ketamine® - 1 
mg/kg] in the same syringe applied intravenously (IV) 
followed by endotracheal intubation; anesthesia was 
maintained with isoflurane4 [Isoforine®]. The electro-
poration parameters consisted of eight unipolar square 
electric pulses with frequencies of 1 Hz and 1000 V/
cm, lasting 100 μs each and delivered by six needle 
electrodes arranged in rows (parallel array) with dis-
tances of 0.3 mm between them using pulse generator 
LC BK-100 (São Paulo, SP, Brazil). All the extension 
of the primary tumor as well as the regional metastasis 
was covered with the needles. Antitumor response 
was performed by clinical examination according to 
RECIST guideline defined as measurable tumor lesions 
in at least one dimension with a minimum size of 10 
mm caliper measurement [1]
At 28-day post-ECT complete remission of the 
primary tumor and metastatic foci was achieved (Fig-
ure 1B and D). CR of lymph node was considered based 
on its reduction < 10 mm (at baseline examination 0.5 
cm³) and also negative FNA. The subject was followed-
up monthly by clinical examination (measurement of 
lymph node was classified as non-measurable due to 
< 10 mm in its axis) and 120 days after ECT, subman-
dibular and retropharyngeal lymph nodes enlargement 
was noted 0.4 cm³ and 2.77 cm³, respectively. FNA of 
both lymph nodes confirmed tumor recurrence metas-
tasis (Figure 1E). Then, a second ECT approach was 
performed as mentioned above, however, based on 
the previous human literature [3,4,7] it was proposed 
adding to bleomycin the calcium gluconate5 [Calcium 
gluconate® 10%]. The dose of calcium gluconate was 
diluted in an isotonic 0.9% NaCl solution resulting in 
a low concentration at 9 mM, injected in both meta-
static lymph nodes (submandibular total volume: 1.4 
mL; retropharyngeal total volume: 0.5 mL) and pulses 
were delivered immediately after drug administration. 
One-week post-second ECT and CaEP, PR was 
observed in retropharyngeal lymph node (1.31 cm³) and 
CR in submandibular lymph node (non-measurable). 
No systemic adverse effects were observed. Local ad-
verse effects were considered mild as transitory edema 
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and ulceration post-ECT and CaEP that resolved in 
21 days after use of cefovexin6 [Convenia® - 0.1 mg/
kg SC single dose] plus non-steroidal anti-inflamma-
tory Piroxicam7 [Anflene® 0.3 mg/kg once daily for 7 
days]. The patient achieved CR at 28-day post-second 
ECT+CaEP observed by non-measurable lymph nodes 
and negative FNA with scar and fibrous tissue locally 
(Figure 1F). Clinical outcome can be observed in Table 
1. Five months disease free interval was achieved (af-
ter second ECT and CaEP), however, at this moment, 
recurrence was observed in the retropharyngeal lymph 
node confirmed by FNA (9 months after first session). 
The owner declined a new ECT session, and submitted 
the patient to surgical excision, but during surgery a 
cardio-respiratory arrest occurred, and patient died 
presenting overall survival of 9 months. The owner 
declined a post-mortem examination. 
DISCUSSION
Feline cutaneous malignant melanoma is 
an aggressive disease with a short survival time for 
the patients (mean 4.5 months) [15]. On the other 
hand, canine cutaneous melanoma seems to be less 
aggressive and metastatic [11] than feline cutaneous 
melanoma [12,15] prognosis for feline cutaneous 
melanoma seems to be poor, as is seen in a metastatic 
human melanomas and cats could be an interesting 
spontaneous model for human cutaneous metastatic 
melanomas. According to the previous literature, the 
mean survival time after surgical removal of cutaneous 
metastatic melanoma in cats is 4.5 months [15], resem-
bling human cutaneous melanoma. 
Due the poor prognosis in this case, the owner 
rejected surgical treatment and accepted a the ECT as 
a more conservative therapeutic approach. Recently, it 
was observed in canine oral malignant melanoma that 
ECT generates an increase of cytotoxic T-cells alon-
gside a decrease of regulatory T-cells post-treatment, 
indicating that activation of immune system occurs 
delaying metastatic lesions [10]. CaEP is a novel an-
ticancer treatment that has been study in the past years 
due to its selective killing cancer cells by necrosis and 
danger signals (expression of ATP, calrecticulin and 
HMGB1) [7]. The CaEP induces supraphysiological 
calcium influx into neoplastic cells leading to acute 
ATP depletion and necrosis of tumor cells [7]. Howe-
ver, since this is singular case report, we were not able 
to correlate immune system alteration with the CaEP. 
The use of CaEP could be an interesting thera-
peutic choice for both human and veterinary medicine. 
Previous in vitro studies showed the effect of CaEP and 
bleomycin electroporation on three different cancer cell 
spheroids (breast, cancer and colon cancer) and normal 
dermal fibroblast spheroids, showing spheroid size 
reduction in all three cancers cells but not in normal 
cell spheroids [5]. These interesting results indicated 
that normal cells seem less sensitive to CaEP [5]. The 
first randomized clinical trial in humans with cutaneous 
metastases treated with CaEP or ECT using bleomycin, 
showed similar results between both techniques [8]. 
Table 1. Clinical outcome after first and second electrochemotherapy treatments. 
Clinical measurement/Adverse effects
1st session ECT D0 D7 D14 D21 D28
Primary tumor (per-
ipalpebral plaque) 0.19 cm
3
Local edema, 
ulceration, and 
crust
Ulceration Crust
CR observed by scar 
tissue with palpebral 
retraction
Submandibular LN 0.5 cm
3 
(FNA +)
Local edema, 
and crust
Crust  
(resolution of 
edema)
LN non-
measurable 
(<10 mm)
non-measurable (<10 
mm) and FNA -
2nd session ECT (120 days after 1st session ECT)
Submandibular LN 0.4 cm3 non-measurable (<10 mm)
Local ulcer-
ation, edema 
and crusts
Crust Scar tissue (FNA -)
Retropharyngeal LN 2.77 cm3 1.31 cm
3; no 
local AE
Local ulcer-
ation, edema 
and crusts
Crust (non-
measurable) Scar tissue (FNA -)
FNA: Fine needle aspiration; LN: Lymph node; ECT: Electrochemotherapy; AE: Adverse effects.
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Figure 1. Metastatic cutaneous malignant melanoma in a cat. A- primary cutaneous peripalpebral plaque (arrow) diagnosed as a malignant melanoma 
by biopsy. B- Complete remission of the peripalpebral lesion (arrow), 28 days after electrochemotherapy. C- Submandibular lymph node enlargement 
(red dotted circle), diagnosed as a metastatic melanoma site by fine needle biopsy. D- Submandibular lymph node remission and crust formation (red 
dotted circle), 28 days after electrochemotherapy (ECT). E- Lymph node metastasis relapse (redo dotted circle) after four months of the previous ECT 
with bleomycin. Complete remission of the lymph node metastasis (red dotted circle), 28 days after ECT plus CaEP.
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However, seems that tumor cells are more sensitive 
to bleomycin than normal ones [2]. Thus, need to be 
conducted to better understand the complex mechanism 
behind the CaEP [3-7] 
A previous study compared the use of bleomy-
cin with calcium compounds as calcium chloride and 
calcium glubionate [5]. These authors demonstrated 
decreased cell viability in three cancer cell lines inde-
pendent of calcium compound [5], indicating the use 
of different calcium compounds associated with CaEP. 
Based on this fact, it was use calcium gluconate due 
the readiness way to be acquired. It was demonstrated 
a good clinical response with its use, showing tempora-
rily tumor remission from the case presented (disease 
free-interval of five months) when compared to other 
report (two months) [8]. A previous case report recor-
ded the use of ECT and CaEP in canine melanoma, 
observing similar results [8], as well as observed in 
another study using combination of ECT and calcium 
electroporation,  suggesting that this approach could be 
used as a strategy to enhance immune system response 
and improve survival in patients with disseminated 
malignant melanoma [4]. 
This description showed that ECT associated 
with CaEP improved outcome of regional melanoma 
lymph node metastasis in a cat. Further investigations 
are needed to understand the use of CaEP in patients 
with metastasis as well as evaluate the use of both 
modalities to determine its synergistic effect.
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